INDICATIONS FOR RADIATION THERAPY

2D and 3D conformal radiation therapy techniques are considered medically necessary for treatment of pancreatic cancer.

Neoadjuvant (Pre-Operative) or Resectable or Borderline Resectable without evidence of metastatic
- No standard treatment regimen currently exists for this subset of patients. If neoadjuvant radiation therapy is delivered, a dose of 45-54Gy in 1.8-2.5Gy fractions or 36Gy in 2.4 fractions are viable options.

Adjuvant (Post-Operative) Resectable Without Evidence of Metastatic Disease
- For resected cases (45-46Gy in 1.8-2Gy fractions) to the clinical target volume, followed by boost (5-9Gy). Up to 31 fractions.

Unresectable/Locally Advanced Without Evidence of Metastatic Disease
- Radiation delivered in 45-54Gy (1.8-2.5Gy fractions or 36Gy in 2.4 fractions). Up to 30 fractions.

Palliative
- Radiation delivered in 25-36Gy in 2.4-5.0Gy fractions is usual for patients with metastatic disease who require palliation for obstruction or pain. Up to 15 fractions.

Local Recurrence after Resection without Evidence of Systemic Metastatic Disease
- Adjuvant chemotherapy or chemoradiation if no previous radiation given. Up to 30 fractions.

TREATMENT OPTIONS REQUIRING PHYSICIAN REVIEW

Intensity Modulated Radiation Therapy (IMRT)
IMRT is not indicated as a standard treatment option and should not be used routinely for the delivery of radiation therapy for pancreatic cancer. IMRT is strictly defined by the utilization of inverse planning

* National Imaging Associates, Inc. (NIA) is a subsidiary of Evolent Health LLC.

1—Pancreatic Cancer
modulation techniques. IMRT may be appropriate for limited circumstances in which radiation therapy is indicated and 3D conformal radiation therapy (3D-CRT) techniques cannot adequately deliver the radiation prescription without exceeding normal tissue radiation tolerance, the delivery is anticipated to contribute to potential late toxicity or tumor volume dose heterogeneity is such that unacceptable hot or cold spots are created.

Clinical rationale and documentation for performing IMRT rather than 2D or 3D-CRT treatment planning and delivery will need to:

- Demonstrate how 3D-CRT isodose planning cannot produce a satisfactory treatment plan (as stated above) via the use of patient-specific dose volume histograms and isodose plans.

- Provide tissue constraints for both the target and affected critical structures.

Per RTOG 1102,\(^2,3\) for neoadjuvant, definitive, palliative, and recurrent disease, not more than 30% of the total volume of kidneys can received \(\geq 18\)Gy. If only one kidney is functional, not more than 10% of the volume can receive \(\geq 18\)Gy. Maximum dose to stomach, duodenum, and jejunum is 55Gy. Mean dose of liver cannot exceed 30Gy. Maximum dose to D0.03cc of spinal cord must be \(\leq 45\)Gy.

Per RTOG 0848,\(^4\) for adjuvant therapy, mean dose to bilateral kidneys must be \(< 18\)Gy. If only one kidney is functional, not more than 15% of that kidney can receive \(\geq 18\)Gy, and not more than 30% can received \(\geq 14\)Gy. Maximum dose to stomach, duodenum, and jejunum is \(\leq 54\)Gy, < 10% of each organ volume can receive between 50 and 53.99Gy, < 15% of the volume of each organ can received between 45 and 49.99Gy. Mean dose of liver must be \(\leq 25\)Gy. Maximum dose to D0.03cc of spinal cord must be \(\leq 45\)Gy.

**Stereotactic Body Radiation Therapy (SBRT)**\(^1\)

Stereotactic Body Radiation Therapy (SBRT) is appropriate to treat locally advanced or recurrent disease without evidence of distant metastasis or to treat a previously irradiated field.

**Proton Beam Radiation Therapy**

Proton beam is not an approved treatment option for pancreatic cancer. Proton beam has not been proven a superior treatment to conventional radiation therapy.

**Intra Operative Radiation Therapy (IORT)**

The role of intraoperative radiation therapy for pancreatic cancer is controversial but may be reasonable for patients undergoing resection that may result in closer involved margins. IORT may be considered on a case-by-case basis.

---

**BACKGROUND**

Pancreatic cancer typically occurs later in life. Risk factors include smoking, alcohol use, obesity, diabetes, and certain chemical exposures. Pancreatitis has also been shown to have an increased risk
of developing pancreatic cancer. Surgical resection is potentially the only curative approach, but most patients present with more advanced stage disease. Overall, the actuarial five-year survival rate is approximately 20%.

The goal of these guidelines is to delineate appropriate indications of the employment of radiation therapy in the treatment of pancreatic cancer and to define suitable methods of delivery of radiation therapy for these indications.

### POLICY HISTORY

<table>
<thead>
<tr>
<th>Date</th>
<th>Summary</th>
</tr>
</thead>
<tbody>
<tr>
<td>January 2022</td>
<td>Added: Dose constraints for neoadjuvant, definitive, palliative and recurrent disease based on RTOG 1102 and dose constraints for adjuvant therapy based on RTOG 0848.</td>
</tr>
</tbody>
</table>
| February 2021 | Deleted: Stereotactic Body Radiation Therapy (SBRT) is considered medically necessary for the treatment of pancreatic cancer. If requested a physician review is required.  \  
               | Added: Stereotactic Body Radiation Therapy (SBRT) is appropriate to treat locally advanced or recurrent disease without evidence of distant metastasis or to treat a previously irradiated field |
| February 2020 | • Stereotactic Radiation Therapy:  \  
                                  | Deleted: Stereotactic Body Radiation Therapy (SBRT) is not currently an approved treatment option for pancreatic cancer.                              \  
                                  | Added: Stereotactic Body Radiation Therapy (SBRT) is considered medically necessary for the treatment Pancreatic Cancer                            |
| February 2019 | • Added and updated references                                                                                                                                                                         |
REFERENCES


ADDITIONAL RESOURCES


Reviewed / Approved by NIA Clinical Guideline Committee
GENERAL INFORMATION

It is an expectation that all patients receive care/services from a licensed clinician. All appropriate supporting documentation, including recent pertinent office visit notes, laboratory data, and results of any special testing must be provided. If applicable: All prior relevant imaging results and the reason that alternative imaging cannot be performed must be included in the documentation submitted.

Disclaimer: National Imaging Associates, Inc. (NIA) authorization policies do not constitute medical advice and are not intended to govern or otherwise influence the practice of medicine. These policies are not meant to supplant your normal procedures, evaluation, diagnosis, treatment and/or care plans for your patients. Your professional judgement must be exercised and followed in all respects with regard to the treatment and care of your patients. These policies apply to all Evolent Health LLC subsidiaries including, but not limited to, National Imaging Associates (“NIA”). The policies constitute only the reimbursement and coverage guidelines of NIA. Coverage for services varies for individual members in accordance with the terms and conditions of applicable Certificates of Coverage, Summary Plan Descriptions, or contracts with governing regulatory agencies. NIA reserves the right to review and update the guidelines at its sole discretion. Notice of such changes, if necessary, shall be provided in accordance with the terms and conditions of provider agreements and any applicable laws or regulations.